Navigation Links
Conatus Pharmaceuticals Initiates Phase II Clinical Trial in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus (HCV)
Date:1/28/2010

SAN DIEGO, Jan. 28 /PRNewswire/ -- Conatus Pharmaceuticals Inc. announced today the initiation of a Phase II clinical trial evaluating CTS-1027 in combination with pegylated interferon (Pegasys®) and ribavirin (Copegus®) in refractory HCV patients.  Antiviral activity, safety and tolerability of the triple combination will be assessed after up to 48 weeks of therapy.

"There is a significant unmet medical need in HCV patients who have not responded to pegylated interferon and ribavirin.  These patients often progress to cirrhosis, a life-threatening condition.  CTS-1027 has the potential to increase the effectiveness of the combination of pegylated interferon and ribavirin in this population," said Dr. Paul J. Pockros, Head, Division of Gastroenterology and Director of the SC Liver Research Consortium and The Scripps Clinic in La Jolla, CA.

CTS-1027 is an oral, small molecule compound that inhibits the activity of key members of a class of protease enzymes, the matrix metalloproteinases or MMPs. CTS-1027's anti-inflammatory and anti-fibrotic effects have been well-established in models of acute hepatitis and liver fibrosis. In addition, CTS-1027 has been shown to reduce and/or block HCV replication in in vitro preclinical models.  

This clinical trial is an open-label design testing an optimized dose of CTS-1027 in combination with Pegasys® and Copegus® in HCV-infected patients who were prior null responders to pegylated interferon and ribavirin treatment. Dosing will last for up to 48 weeks. The Company expects approximately 60 patients to be enrolled. The clinical trial will be conducted at up to fifteen medical centers in the U.S. Additional information about the trial can be found at:

SOURCE Conatus Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Conatus Pharmaceuticals to Present at the Montgomery Healthcare Conference
2. Conatus Pharmaceuticals Initiates a Second Phase 2 Clinical Trial for the Treatment of Hepatitis
3. Conatus Pharmaceuticals Reports Positive Results of CTS-1027 in Multiple Preclinical Studies of Liver Disease
4. Intercept Pharmaceuticals Raises $25 Million Series B Financing
5. Poniard Pharmaceuticals Announces Phase 2 Trial of Picoplatin in Metastatic Colorectal Cancer Meets Primary Endpoint and Study Objectives
6. Amylin Pharmaceuticals to Webcast Year-End Financial Results
7. Cumberland Pharmaceuticals Donates Caldolor(R) to Haitian Relief Effort
8. Sagent Pharmaceuticals Launches Pamidronate Disodium Injection
9. Endo Pharmaceuticals Announces Receipt of Paragraph IV Certification
10. Barclays Wealth Recommends Increasing Exposure to Laggard Sectors Including Consumer Staples, Pharmaceuticals and Telecoms
11. Jiangbo Pharmaceuticals Osteomyelitis Treatment Tablets to be Included in Chinas National Insurance Directory
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... -- Zimmer Holdings, Inc. (NYSE: ZMH and ... and organizational structure of the combined company following the ... the combined organization will leverage the strength of both ... the new brand to be rolled out across the ... future leadership team is committed to establishing Zimmer Biomet ...
(Date:10/30/2014)... ANGELES , Oct. 30, 2014   ... company devoted to bringing new products to market, ... drug called TetraStem. TetraStem is a topical liquid ... delivery system that can convert oral medication active ... registered as a first aid antibiotic to help ...
(Date:10/30/2014)... , Oct. 30, 2014  Nektar Therapeutics (Nasdaq: ... the third quarter ended September 30, 2014 on Thursday, ... markets. Howard Robin , president and chief executive ... results beginning at 5:00 p.m. Eastern Time (ET)/2:00 p.m. ... and a live audio-only Webcast of the conference call ...
Breaking Medicine Technology:Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 2Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 3Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 4Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 5Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 6Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 7Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 8Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 9ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 2ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 3Nektar to Announce Financial Results for the Third Quarter 2014 on Thursday, November 6, 2014, After Close of U.S.-Based Financial Markets 2
... SAN DIEGO, Nov. 28, 2011 OncoSec Medical ... advanced-stage OMS ElectroOncology therapies to treat skin cancer ... Punit Dhillon, President and CEO, will be presenting ... Conference in New York City. (Logo: ...
... 2011 /PRNewswire-Asia/ -- ShangPharma Corporation (NYSE: SHP ... and biotechnology research and development outsourcing company, today announced ... investor conferences in December 2011: Ms. Lan ... ShangPharma, will present at the following conferences: ...
Cached Medicine Technology:OncoSec to Present at 15th Annual Biotech and Specialty Pharmaceuticals Conference 2ShangPharma to Attend Two Upcoming Investor Conferences 2
(Date:10/31/2014)... Chico, CA. (PRWEB) October 31, 2014 ... best known for its small scale BioPro™ biodiesel ... equipment that will further improve the performance and ... , The GL95/MC12/BD380 trio will recover ... is mixed in with the glycerin by-product produced ...
(Date:10/31/2014)... Denver, Colorado (PRWEB) October 31, 2014 Daily ... new method is actually described as the fastest fat loss ... results in less than a month. , There is no ... fat loss eBook of all time. The new nutrition and ... popular nutrition and fitness expert. , According to the ...
(Date:10/31/2014)... (PRWEB) October 31, 2014 Activz ... Activz Silver line offering natural silver healing ... For over a century, silver has been used to ... Activz Silver products is the most advanced version available. ... a unique chemical structure that supports the existing healing ...
(Date:10/31/2014)... duration of treatment and cost, patients with early ... breast irradiation (APBI) with proton therapy versus whole ... The University of Texas MD Anderson Proton Therapy ... study based on typical patient characteristics, researchers used ... eight different types of partial and whole breast ...
(Date:10/31/2014)... 31, 2014 The Suspension Revolution review ... program was developed by Dan Long, a suspension training ... a fitness professional and life coach. The author of ... toned muscles is not impossible , The Suspension Revolution ... training. Suspension training promises efficiency when it comes to ...
Breaking Medicine News(10 mins):Health News:Springboard Biodiesel Announces Release of New and Unique Methanol Recovery and Glycerin Treatment Equipment 2Health News:Springboard Biodiesel Announces Release of New and Unique Methanol Recovery and Glycerin Treatment Equipment 3Health News:Xtreme Fat Loss Diet Review Reveals How to Transform Your Body in 25 Days 2Health News:New Collection of Nano-particle Natural Silver Products by Activz Whole-Food Nutrition 2Health News:New Collection of Nano-particle Natural Silver Products by Activz Whole-Food Nutrition 3Health News:New Collection of Nano-particle Natural Silver Products by Activz Whole-Food Nutrition 4Health News:Proton therapy shown to be less costly than some alternative radiotherapy techniques 2Health News:Proton therapy shown to be less costly than some alternative radiotherapy techniques 3Health News:Suspension Revolution Review Reveals Dan Long's New Suspension Workout Plan 2
... Reporter , TUESDAY, April 19 (HealthDay News) -- The first ... disease could double the number of Americans defined as having ... Alzheimer,s Association and the U.S. National Institute of Aging, differ ... been in use since 1984. First, Alzheimer,s is ...
... , TUESDAY, April 19 (HealthDay News) -- Minority ... more likely to die in early childhood than whites, a ... nearly 20,000 black, Hispanic and white infants born with congenital ... Overall, black infants were 32 percent more likely to die ...
... . FRANKFURT, Germany. It is a rare ... start experiencing vision impairments, which two to three years ... indication of a progressive destruction of brain cells. Later ... finally, failure of all motor abilities. In this last ...
... at the University of California, San Diego School of ... found in people may be useful as a future ... early and, in sufficient concentration, used as a treatment ... led by Richard Schwab, MD, assistant clinical professor of ...
... HealthDay Reporter , TUESDAY, April 19 (HealthDay News) -- About ... were going to get all of the recommended vaccinations, and ... immunizations, two new surveys find. Pediatricians and infectious disease ... about a supposed autism/MMR (measles, mumps, rubella) link -- ...
... 2011, Springer will publish Translational Behavioral Medicine: ... the Society of Behavioral Medicine. The journal will ... Evidence Implementation. Translational Behavioral Medicine ... online-first publication. Its aim is to engage, ...
Cached Medicine News:Health News: Alzheimer's Cases Could Double With New Guidelines: Expert 2Health News: Alzheimer's Cases Could Double With New Guidelines: Expert 3Health News:Minority Kids With Heart Defects More Likely to Die in Childhood 2Health News:Hope for children with rare genetic defect 2Health News:Hope for children with rare genetic defect 3Health News:A cancer marker and treatment in 1? 2Health News:A cancer marker and treatment in 1? 3Health News:Most Parents Vaccinate Kids, Trust Docs' Advice on Shots 2Health News:Most Parents Vaccinate Kids, Trust Docs' Advice on Shots 3Health News:Springer launches new journal, Translational Behavioral Medicine: Practice, Policy, Research 2
...
...
...
EDM Lumbar Drainage Kit with and without Bioglide are fabricated of radiopaque (barium impregnated) silicone tubing, and are packaged with stainless steel stylets inserted in the lumen....
Medicine Products: